Survival in low-, intermediate-, and high-risk patients by therapy. (A) Event-free survival. (B) Overall survival. (C) Progression-free survival. In low-risk patients, 6-year EFS, OS, and PFS rates were 80.9% vs 80.7% (P = .898), 100% vs 81.2% (P = .114), and 85.2% vs 95.2% (P = .365) in the imatinib group vs the allo-HSCT group, respectively. In intermediate-risk patients, 6-year EFS, OS, and PFS rates were 47.1% vs 61.9% (P = .788), 61.3% vs 81.3% (P = .773), and 55.7% vs 92.9% (P = .047) in the imatinib group vs the allo-HSCT group, respectively. In high-risk patients, 5-year EFS, OS, and PFS rates were 9.3% vs 66.7% (P = .030), 17.7% vs 100% (P = .008), and 18.8% vs 100% (P = .006) in the imatinib group vs the allo-HSCT group, respectively.